MX2017006063A - Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal. - Google Patents

Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal.

Info

Publication number
MX2017006063A
MX2017006063A MX2017006063A MX2017006063A MX2017006063A MX 2017006063 A MX2017006063 A MX 2017006063A MX 2017006063 A MX2017006063 A MX 2017006063A MX 2017006063 A MX2017006063 A MX 2017006063A MX 2017006063 A MX2017006063 A MX 2017006063A
Authority
MX
Mexico
Prior art keywords
methods
apoaequorin
same
neuronal inflammation
containing compositions
Prior art date
Application number
MX2017006063A
Other languages
English (en)
Inventor
Y Underwood Mark
R Moyer James Jr
Original Assignee
Quincy Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quincy Bioscience Llc filed Critical Quincy Bioscience Llc
Publication of MX2017006063A publication Critical patent/MX2017006063A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se relaciona con métodos de preacondicionamiento de neuronas para reducir la inflamación neuronal en un paciente. Estos métodos incluyen una etapa de administrar apoacuorina a un paciente, en donde las neuronas del paciente se preacondicionan para reducir la inflamación neuronal subsecuente en el paciente.
MX2017006063A 2014-11-11 2015-11-11 Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal. MX2017006063A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462078099P 2014-11-11 2014-11-11
PCT/US2015/060116 WO2016077437A1 (en) 2014-11-11 2015-11-11 Apoaequorin-containing compositions and methods of using same to treat neuronal inflammation

Publications (1)

Publication Number Publication Date
MX2017006063A true MX2017006063A (es) 2017-07-27

Family

ID=55954981

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017006063A MX2017006063A (es) 2014-11-11 2015-11-11 Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal.

Country Status (24)

Country Link
US (1) US20180214516A1 (es)
EP (1) EP3217998B1 (es)
JP (1) JP6861162B2 (es)
KR (1) KR20170072350A (es)
CN (1) CN107106649A (es)
AU (2) AU2015346430B2 (es)
BR (1) BR112017009599A2 (es)
CA (1) CA2966891C (es)
DK (1) DK3217998T3 (es)
ES (1) ES2910021T3 (es)
HK (2) HK1243343A1 (es)
HR (1) HRP20220749T1 (es)
HU (1) HUE059107T2 (es)
IL (1) IL252070B (es)
LT (1) LT3217998T (es)
MA (1) MA40959A (es)
MX (1) MX2017006063A (es)
NZ (1) NZ731340A (es)
PL (1) PL3217998T3 (es)
PT (1) PT3217998T (es)
RS (1) RS63269B1 (es)
SG (2) SG10202108723PA (es)
SI (1) SI3217998T1 (es)
WO (1) WO2016077437A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ214563A (en) * 1984-12-31 1991-05-28 Univ Georgia Production of apoaeqorin using recombinant dna
CA2717322C (en) * 2008-03-11 2017-07-11 Quincy Bioscience, Llc Apoaequorin-containing compositions and methods of using same
US20110130336A1 (en) 2009-10-16 2011-06-02 Quincy Bioscience, Llc Method of treating ischemic injury using apoaequorin
DK2780027T3 (en) * 2011-11-15 2017-09-25 Quincy Bioscience Llc Apoaequorin for limiting ischemia-induced nerve damage.
PT2900253T (pt) * 2012-09-27 2019-02-25 Quincy Bioscience Llc Métodos para aliviar os sintomas da esclerose múltipla baseados em composições contendo apoequorina

Also Published As

Publication number Publication date
JP2017535607A (ja) 2017-11-30
WO2016077437A1 (en) 2016-05-19
PL3217998T3 (pl) 2022-07-11
CN107106649A (zh) 2017-08-29
NZ731340A (en) 2018-11-30
LT3217998T (lt) 2022-04-11
CA2966891A1 (en) 2016-05-19
SI3217998T1 (sl) 2022-07-29
BR112017009599A2 (pt) 2017-12-19
JP6861162B2 (ja) 2021-04-21
HK1244223A1 (zh) 2018-08-03
EP3217998A4 (en) 2018-06-27
AU2015346430A1 (en) 2017-05-25
HUE059107T2 (hu) 2022-10-28
EP3217998A1 (en) 2017-09-20
IL252070B (en) 2022-06-01
AU2015346430B2 (en) 2019-01-03
KR20170072350A (ko) 2017-06-26
SG10202108723PA (en) 2021-09-29
ES2910021T3 (es) 2022-05-11
HRP20220749T1 (hr) 2022-09-02
CA2966891C (en) 2023-07-04
PT3217998T (pt) 2022-04-05
MA40959A (fr) 2017-09-19
RS63269B1 (sr) 2022-06-30
HK1243343A1 (zh) 2018-07-13
EP3217998B1 (en) 2022-03-23
US20180214516A1 (en) 2018-08-02
SG11201703690XA (en) 2017-06-29
AU2018279057A1 (en) 2019-01-17
IL252070A0 (en) 2017-07-31
DK3217998T3 (da) 2022-04-25

Similar Documents

Publication Publication Date Title
TW201613636A (en) Methods of treating Alzheimer's Disease
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
TW201613935A (en) Tricyclic heterocycles as BET protein inhibitors
WO2019040106A3 (en) COMPOUNDS, RELATED SALTS AND METHODS FOR THE TREATMENT OF DISEASES
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
MX365366B (es) Formulaciones tópicas y orales que comprenden taurina y magnesio para la prevención y el tratamiento del acné.
MX2018008645A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano.
MX2020003762A (es) Composiciones cosmeticas y metodo para tratar la piel.
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
MX2017006019A (es) Apilimod para uso en el tratamiento de melanoma.
EP3185862A4 (en) PROTECTIVE METALOTHION ANALOG COMPOUNDS, THEIR COMPOSITIONS AND USE THEREOF IN THE TREATMENT OF PATHOGENIC DISEASES
SG10201811078XA (en) Method Of Treatment Of Hypoxia Inducible Factor (HIF)-Related Conditions
MX2018008643A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5] -decano.
NZ745187A (en) 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
PH12016501658A1 (en) Sialylated glycoprotein compositions and uses thereof
MX2019001337A (es) Métodos para tratar y prevenir efectos secundarios por tratamiento de cáncer.
PH12017501979A1 (en) Pharmaceutical compound
MX2017006063A (es) Composiciones que contienen apoacuorina y metodos de uso de las mismas para el tratamiento de inflamacion neuronal.
MX2019004179A (es) Composiciones de apilimod y metodos para utilizar las mismas en el tratamiento de la enfermedad de alzheimer.
NZ747201A (en) (+)-azasetron for use in the treatment of ear disorders
MX2018015240A (es) Composiciones que comprenden timolol y su uso en el tratamiento de rosacea mediante administracion topica.
EP3501491A4 (en) ANTI-WRINKLE COSMETIC COMPOSITION, USE OF THIS COMPOSITION AND ANTI-WRINKLE TREATMENT METHOD